Determinants of pulmonary function improvement in patients with scleroderma and intestitial lung disease

Clinical and Experimental Rheumatology

Volumn 25, Issue 5, 2007, Pages 734-739

  Tzelepis, George E ^a   Plastiras, Sotiris C ^a   Karadimitrakis, Stylianos P ^a   Vlachoyiannopoulos, Panayiotis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cyclophosphamide; Interstitial lung disease; Pulmonary fibrosis; Pulmonary function; Scleroderma

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; PREDNISOLONE; STEROID;

ADULT; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INDEPENDENT VARIABLE; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SCLERODERMA; SHORT COURSE THERAPY; STATISTICAL MODEL; TREATMENT DURATION;

ADULT; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISOLONE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 37348998908     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DIOT E, GIRAUDEAU B, DIOT P et al.: Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116: 715-20.
2. IOANNIDIS JP, VLACHOYIANNOPOULOS PG, HAIDICH AB et al.: Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
3. MEDSGER TA JR: D-penicillamine treatment of lung involvement in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1987; 30: 832-4.
4. PLASTIRAS SC, KARADIMITRAKIS SP, ZIAKAS PD, VLACHOYIANNOPOULOS PG, MOUTSOPOULOSIHM, TZELEPIS GE: Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
5. VLACHOYIANNOPOULOS PG, DAFNI UG, PAKAS I, SPYROPOULOU-VLACHOU M, STAVROPOULOS-GIOKAS C, MOUTSOPOULOS HM: Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000; 59: 359-67.
6. AIRÒ P, DANIELI E, PARRINELLO G et al.: Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22: 573-8.
7. AKESSON A, SCHEJA A, LUNDIN A, WOLLHEIM FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729-35.
8. APRAS S, ERTENLI I, OZBALKAN Z et al.: Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48: 2256-61.
9. CALGÜNERI M, APRAS S, OZBALKAN Z et al.: The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003; 22: 289-94.
10. D'ANGELO S, CUOMO G, PAONE C, COLUTTA E, LA MG, VALENTINI G: Low-dose intravenous cyclophosphamide in systemic sclerosis: A preliminary safety study. Clin Rheumatol 2003; 22: 393-6.
11. DAVAS EM, PEPPAS C, MARAGOU M, ALVANOU E, HONDROS D, DANTIS PC: Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18: 455-61.
12. GIACOMELLI R, VALENTINI G, SALSANO F et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.
13. PAKAS I, IOANNIDIS JP, MALAGARI K, SKOPOULI FN, MOUTSOPOULOS HM, VLACHOYIANNOPOULOS PG: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
14. SILVER RM, WARRICK JH, KINSELLA MB, STAUDT LS, BAUMANN MH, STRANGE C: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-44.
15. VAN DEN HOOGEN FH, VAN DE PUTTE LB: Treatment of systemic sclerosis. Curr Opin Rheumatol 1994; 6: 637-41.
16. WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
17. GRIFFITHS B, MILES S, MOSS H, ROBERTSON R, VEALE D, EMERY P: Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371-8.
18. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
19. HOYLES RK, ELLIS RW, WELLSBURY J et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
20. SUBCOMMITTEE FOR SCLERODERMA CRITERIA OF THE AMERICAN RHEUMATISM ASSOCIATION DIAGNOSTIC AND THERAPEUTIC CRITERIA COMMITTEE: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
21. MILLER AB, HOOGSTRATEN B, STAQUET M, WINKLER A: Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
22. KOWAL-BIELECKA O, KOWAL K, ROJEWSKA J et al.: Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: A retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005; 64: 1343-6.
23. STEEN VD, LANZ JK JR, CONTE C, OWENS GR, MEDSGER TA JR: Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-6.
24. VARAI G, EARLE L, JIMENEZ SA, STEINER RM, VARGA J: A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325-9.
25. STEEN VD, MEDSGER TA JR: Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-9.
26. DEMARCO PJ, WEISMAN MH, SEIBOLD JR et al.: Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-9.
27. PLASTIRAS SC, VLACHOYIANNOPOULOS PG, TZELEPIS GE: Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 2006; 45: 1572.
28. GREENWALD GI, TASHKIN DP, GONG H et al.: Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med 1987; 83: 83-92.
29. DASS S, FERNANDES C, GRIFFITHS B, EMERY P: Safety and Efficacy of Prolonged Treatment of Fibrosing Alveolitis in Scleroderma with Cyclophosphamide. Arthritis Rheum 2005 (Suppl.); p. 165.